Blog

Insights on peptide prescribing, compounding, and regulatory developments.

April 1, 2026·5 min read

Informed Consent for Compounded Peptides: What You Need to Document

Informed consent for compounded medications carries unique requirements. Learn what to include, common mistakes that create liability, and how to keep consent forms current as regulations change.

March 28, 2026·7 min read

BPC-157 Prescribing Guide: Dosing, Protocols, and Clinical Considerations

Everything physicians need to know about prescribing BPC-157. Mechanism of action, FDA regulatory status, dosing protocols, lab monitoring, contraindications, and informed consent considerations.

March 24, 2026·6 min read

503A vs 503B Compounding Pharmacies: What Prescribers Need to Know

A clear breakdown of the differences between 503A and 503B compounding pharmacies, when to use each, and how to vet a pharmacy partner for peptide prescribing.

March 21, 2026·8 min read

How to Start Prescribing Peptides: A Physician's Complete Guide

A practical guide for physicians entering peptide therapy. Covers which peptides are legally available, how to choose a compounding pharmacy, basic protocol structure, and compliance essentials.

March 18, 2026·6 min read

The Cash-Pay Prescribing Stack: Software for Clinics Beyond Insurance

Insurance-based e-prescribing doesn't work for cash-pay clinics. Here's what the emerging software stack looks like for clinics prescribing compounded medications, peptides, and specialty compounds.

March 14, 2026·12 min read

FDA Peptide Reclassification 2026: What the Category 2 to Category 1 Shift Means for Providers and Pharmacies

The FDA is moving key peptides from Category 2 back to Category 1, reopening the compounding market. Here's what providers and compound pharmacies need to know about timelines, compliance, and operational readiness.